SOLASIA PHARMA K.K. O.N. Logo
JP3436500007
A2DN9S
4597.T

SOLASIA PHARMA K.K. O.N.

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2022, SOLASIA PHARMA K.K. O.N. has already paid €0.27 in dividends. The last payout was in March 2022.

Financials

In the last quarter, SOLASIA PHARMA K.K. O.N. had revenue of €1.89M and net profit of -€565.93K

(EUR) September 2026
YoY
Revenue 1.89M 683.19%
Gross profit 958.16K 436.83%
Net profit -565.93K 42.52%
EBITDA -543.52K 42.79%

Fundamentals

Metric Value
Market capitalization
€40.8M
Number of shares
273.01M
52-week high/low
€0.24 - €0.12
Dividends No
Beta
1.18
P/E ratio
-8.55
PEG ratio
-0.10
P/B ratio
5.28
P/S ratio
10.38

Company profile

Solasia Pharma K.K. develops and commercializes drugs in the field of oncology in Japan and other Asian countries. The company offers SP-03 (episil oral liquid) for the protection and relief of oral pain associated with oral mucositis/stomatitis caused by chemotherapy and radiotherapy for cancer; and SP-01 (Sancuso), a transdermal delivery system that delivers granisetron, an anti-emetic into the patient's bloodstream for the treatment of chemotherapy induced nausea and vomiting. It is also developing SP-02 (Darinaparsin), a mitochondrial-targeted agent that has completed phase III clinical study to treat various hematologic and solid cancers; and SP-04 a chemotherapy induced peripheral neuropathy which is in pre-clinical stage. In addition, the company is developing SP-05 (Arfolitixorin) that is in phase III clinical study for the enhancement of antitumor efficacy of fluorouracil, including the treatment for pancreatic cancer, breast cancer, stomach cancer, and head and neck cancers. Solasia Pharma K.K. was founded in 2006 and is based in Tokyo, Japan.

Name
SOLASIA PHARMA K.K. O.N.
CEO
Yoshihiro Arai
Headquarters Tokyo, ty
Japan
Website
IPO
03/27/2017
Employees 22

Ticker symbols

Exchange Symbol
Japan Exchange Group
4597.T
Frankfurt
9SO.F
🍪

Parqet  uses cookies. Learn more